2-Fluoro-6-Methylene Carbocyclic Nucleosides for HBV Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis B virus (HBV) infections, particularly nucleoside/nucleotide analogs, face challenges with long-term efficacy due to the emergence of drug-resistant mutants, as they do not effectively target covalently closed circular DNA, leading to viral rebound upon treatment discontinuation and associated clinical complications.
Innovation Solution
Development of 2′-Fluoro-6′-methylene carbocyclic nucleosides, such as 2′-Fluoro-6′-methylene carbocyclic adenosine (FMCA) and its monophosphate prodrug, which exhibit potent activity against wild-type HBV and drug-resistant mutants, including lamivudine and adefovir-resistant strains, by maintaining effective antiviral activity and reducing viral load.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current nucleoside/nucleotide analogs are used for HBV treatment, then viral replication is suppressed, but drug-resistant mutants emerge leading to treatment failure
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of nucleoside analogs through fluorine substitution at the 2′ position and methylene group addition at the 6′ position of the carbocyclic ring. These structural parameter changes create novel compounds (2′-fluoro-6′-methylene carbocyclic nucleosides) that maintain antiviral activity while overcoming resistance to existing drugs like lamivudine and adefovir, thereby resolving the contradiction between treatment efficacy and viral resistance
Solution Approach 2:
The invention creates composite chemical structures by combining fluorinated carbocyclic sugar moieties with nucleobases, forming hybrid nucleoside analogs that integrate features of multiple existing drug classes. This composite approach produces molecules with enhanced properties that simultaneously achieve viral suppression and resistance to mutant strains
2Duration of action of stationary object
If long-term nucleoside/nucleotide treatment is administered, then viral load is suppressed, but mitochondrial toxicity accumulates
Solution Approach 1:
The patent employs parameter changes by introducing fluorine atoms and methylene groups into the carbocyclic nucleoside structure, which alters the metabolic profile and toxicity characteristics of the compounds. These structural modifications enable long-term administration while reducing mitochondrial toxicity compared to conventional nucleoside analogs, thus resolving the contradiction between treatment duration and harmful side effects
Data Source
AI summary
The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses, especially HBV.